Page 12 - reflections_dyslipidaemia_newsletter5_2023
P. 12
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #5 2023
ADDITIONAL ARTICLES OF INTEREST Dyslipidaemia
EPIDEMIOLOGY
1. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Wadström
BN, et al. Eur Heart J. 2023 Jul 1;44(25):2277-2291.
2. Lipoprotein(a) and coronary artery calcium in comparison with other lipid biomarkers: The multi-ethnic study of
atherosclerosis. Jackson CL, et al. J Clin Lipidol. 2023 Jun 17;S1933-2874(23)00212-X
3. Cardiovascular disease risk assessment using traditional risk factors and polygenic risk scores in the Million
Veteran Program. Vassy JL, et al. JAMA Cardiol. 2023 Jun 1;8(6):564-574.
4. Screening for lipid disorders in children and adolescents: Updated evidence report and systematic review for the
US Preventive Services Task Force. Guirguis-Blake JM, et al. JAMA. 2023 Jul 18;330(3):261-274.
TREATMENT/MANAGEMENT
5. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: A
collaborative analysis of three randomised trials. Ridker PM, et al. Lancet. 2023 Apr 15;401(10384):1293-1301.
6. Nutrition interventions for adults with dyslipidemia: A clinical perspective from the National Lipid Association.
Kirkpatrick CF, et al. J Clin Lipidol. 2023 Jun 2;S1933-2874(23)00185-X
7. Vegetarian or vegan diets and blood lipids: A meta-analysis of randomized trials. Koch CA, et al. Eur Heart J. 2023 Jul
21;44(28):2609-2622.
8. Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of
pooled data from four phase 3 clinical trials. Stroes ESG, et al. Atherosclerosis. 2023 May;373:1-9.
9. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. Nissen SE, et al. JAMA.
2023 Jul 11;330(2):131-140.
10. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. O’Donoghue ML, et al. N Engl J Med. 2022
Nov 17;387(20):1855-1864.
11. Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque. Marfella R, et
al. Atherosclerosis. 2023 Jun 29;117180.doi: 10.1016/j.atherosclerosis.2023.06.971. Online ahead of print.
CONSENSUS STATEMENTS/ REVIEW ARTICLES
12. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European
Atherosclerosis Society. Kronenberg F, et al. Atherosclerosis. 2023 Jun;374:107-120.
13. Familial hypercholesterolemia: Challenges for a high-risk population: JACC Focus Seminar 1/3. Choi D, et al.
Atherosclerosis. 2023 Jun 29;117180. doi: 10.1016/j.atherosclerosis.2023.06.971. Online ahead of print.
14. Cardiovascular outcomes in patients with diabetes and kidney disease: JACC review topic of the week. Morales J,
et al. J Am Coll Cardiol. 2023 Jul 11;82(2):161-170.
TABLE OF CONTENTS
